Organigram Lands Aurora Deal While Curaleaf Refuses to Back Down

The fight over Aurora Cannabis has taken a new turn. Organigram Global has agreed to acquire the company in a transaction that values Aurora's equity at roughly C$561 million, giving Aurora an agreed-upon alternative to the hostile offer already put forward by Curaleaf. Unlike that unsolicited approach, the Organigram deal has the support of both companies' boards, which matters in a takeover contest where directors' recommendations often shape how shareholders respond. British American Tobacco would help finance the acquisition, bringing a major outside source of capital into the transaction and signaling how seriously the backers are taking the effort. Curaleaf, for its part, is not stepping aside. The company says its offer remains the better choice for Aurora shareholders and has sharply criticized Aurora's directors over how they have handled the situation. That sets up a tense stretch where two very different paths are on the table: a negotiated combination that Aurora's leadership endorses, and a hostile bid from a larger multistate operator that is still very much alive. For observers of the cannabis business, the story is a reminder of how much consolidation is happening as companies look for scale in a tough market. Deals like this can reshape competition, shuffle brand portfolios, and change how products reach shoppers, though the real impact will depend on which offer ultimately prevails and on the regulatory approvals required. Shareholders now have a decision to weigh, with competing arguments on price, certainty, and strategy. The coming weeks should show whether Curaleaf raises its pitch, whether Aurora's investors side with their board, or whether Organigram's agreed transaction becomes the one that crosses the finish line.